The Pathophysiology of Acute Coronary Syndrome

1Department of Medical and Surgical Sciences, Magna Graecia University, 88100 Catanzaro, Italy 2Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, Italy 3CMR Unit, Royal Brompton and Harefield Hospital, UB9 6JH London, UK *Correspondence: saderosa@unicz.it (Salvatore De Rosa) Academic Editor: Giuseppe Boriani Submitted: 1 March 2023 Revised: 5 March 2023 Accepted: 7 March 2023 Published: 21 July 2023

erogeneity often represents a hassle to pursue the etiological diagnosis and requires multiple invasive and noninvasive tests. This special issue features a comprehensive overview on the topic, aiming at individuating clinical signs and symptoms of prognostic relevance [10]. The authors also provided a comprehensive review of the intracoronary imaging and coronary physiological techniques useful in this setting, that are currently a key research focus in this area [11,12]. These novel tools complement standard coronary angiography, providing additional information about the culprit lesion and identifying high risk plaque features. A thorough knowledge of their strengths and limitations is key to better understand the most appropriate diagnostic approach [13]. Advanced imaging and angiographic modalities represent only one possible approach to identify highrisk lesions. There is in fact growing interest about the potential role of novel circulating biomarkers of instability [14]. In this regard, plasma levels of trimethylamine N-Oxide (TMAO) are independently associated with plaque rupture and can be helpful to distinguish it from plaque erosion [4,15]. The latter has been instead associated with elevated levels of Neutrophil extracellular traps (NETs) and Interleukin-8 (IL-8).
The immune system and the pro-inflammatory environment play an unquestionable role in patients with ACS, with possible therapeutic implications. One clear example is the evidence that Canakinumab has proven to reduce CV events in patients with prior myocardial infarction (MI), inhibiting the IL-1 mediated inflammatory response [16]. In this issue, Liu et al. [17] report that lower levels of circulating soluble interleukin-1 receptor type 2 (sIL-1R2) were associated with an increased risk of worsened LVEF and adverse clinical outcome at 12 months. In addition, regulatory T-cells have a lower count in ST Elevation Myocardial Infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI) and accurately predict the presence of intramyocardial hemorrhage [18]. An emerging yet powerful tool to detect inflammation nowadays is cardiac imaging. The pericoronary fat attenuation index (pFAI) is in fact a computed tomography biomarker of coronary inflammation, correlated with increased risk of cardiac mortality. The authors found higher pFAI values in diabetic patients with poorer glycemic control [19]. This could rep-resent an additional tool, to identify patients at higher risk of future CV events. Vascular inflammation is a key element in the response of the vessel wall to vascular interventions, more so when a relevant traumatic stimulus is present. Using an approach at the forefront of biomedical technologies, the authors assessed the long-term results of a novel covered stent, useful to treat the dreadful complication of coronary perforation equipped with a biodegradable membrane. This might help to counteract the risks of restenosis and thrombosis, which are usually frequently observed with covered stents [20].
The advent of novel anti-thrombotic drugs has drastically changed the landscape of ACS outcomes. Treatment with more recent P2Y12 inhibitors has in fact proven to be superior to clopidogrel in preventing ischemic CV events. However, the undeniable benefit coming from the use of these potent drugs has been questioned by the increased risk of bleeding events, with potential risk of discontinuation [21]. A sub-analysis of the IDEAL-LDL trial published in this special issue tried to address this concern, demonstrating that potency of P2Y12 inhibitors does not affect adherence to therapy [22]. Randomized trials demonstrated the superiority of complete revascularization over culprit-only revascularization in patients with STEMI, even though this debate is still open. In this context, a metanalysis including 2256 patients showed no significant difference in clinical outcomes among the two strategies, suggesting a tailored approach when dealing with ACS patients with multivessel disease [23].
When dealing with ACS, several are therefore the aspects that merit further investigation, with novel concepts emerging in the last decades. A terse identification of currently unmet clinical needs and a thorough comprehension of the complex pathophysiological mechanisms subtended to ACS are the necessary starting point to fuel the development of new therapeutic and preventive strategies. The articles collected in this special issue sound a bell to some underestimated issues, representing a first step in the appropriate direction, hopefully meeting the need of dedicated literature on this never outdated topic.

Author Contributions
IL and SDR conceptualization and draft of the manuscript. SDR and DT performed a critical revision of the manuscript. All authors read and approved the final manuscript.

Ethics Approval and Consent to Participate
Not applicable.